Dompe announces the FDA has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
24-Jul-2014 -
Dompe announces that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration (FDA).The candidate drug, developed by the research of Dompe, has been designated as an orphan drug for the treatment of neurotrophic keratitis, a ...
growth factors
Orphan Drug Designation